Pozen (Nasdaq: POZN) has secured at least a temporary victory in its battle to protect the pain reliever from generic competition.
The news sent Pozen shares up 3 percent to just under $6 in early trading Friday.
Before the markets opened, Pozen said it had secured a preliminary injunction against Par Pharmaceutical, which planned to make a version of Treximet. Treximet is sold by GlaxoSmithKline under license with Pozen.
The court battle is being waged in federal court in Texas.
Pozen is fighting a patent infringement battle against Par and other providers. A decision is still pending in the case. The injunction remains in effect until the case is decided.
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.